

**Supplementary Table 1.** Univariable HRs and 95% CIs of categorical potential risk factors in relation to incident CKD among the diabetic population for CKD-EPI and MDRD analyses: Tehran Lipid and Glucose Study

Variable	CKD-EPI			MDRD		
	E/N	HR (95% CI)	P value	E/N	HR (95% CI)	P value
<b>Sex</b>						
Men	136/350	1		142/327	1	
Women	216/447	1.22 (0.98–1.51)	0.075	214/353	1.43 (1.16–1.77)	0.001
<b>Age groups, yr</b>						
21–40	12/124	1		24/118	1	
41–60	231/504	6.17 (3.45–11.03)	<0.001	245/423	3.81 (2.50–5.79)	<0.001
>60	109/169	16.85 (9.24–30.71)	<0.001	87/139	6.65 (4.22–10.49)	<0.001
<b>BMI</b>						
Normal	62/146	1		64/129	1	
Overweight	151/341	0.95 (0.70–1.27)	0.712	151/290	0.96 (0.72–1.29)	0.780
Obese	139/310	0.95 (0.71–1.29)	0.758	141/261	0.98 (0.73–1.32)	0.900
<b>Central obesity</b>						
No	87/199	1		85/169	1	
Yes	265/598	1.01 (0.80–1.29)	0.908	271/511	1.05 (0.82–1.34)	0.694
<b>Blood pressure categories</b>						
Normal	55/166	1		56/142	1	
Prehypertension	124/298	1.26 (0.92–1.73)	0.154	140/263	1.42 (1.04–1.94)	0.026
Hypertension	173/333	1.88 (1.39–2.54)	<0.001	160/275	1.78 (1.31–2.41)	<0.001
<b>FPG baseline categories, mmol/L</b>						
<7.22	117/286	1		117/245	1	
7.22–10	118/264	1.17 (0.91–1.52)	0.218	125/227	1.30 (1.01–1.67)	0.044
≥10	117/247	1.43 (1.11–1.85)	0.006	114/208	1.54 (1.19–1.99)	0.001
<b>Glucose-lowering medications</b>						
No	210/521	1		226/452	1	
Yes	142/276	1.65 (1.34–2.05)	<0.001	130/228	1.44 (1.16–1.79)	0.001
<b>Low HDL-C</b>						
No	81/167	1		72/145	1	
Yes	271/630	0.90 (0.70–1.15)	0.379	283/534	1.10 (0.85–1.43)	0.454
<b>Hypertriglyceridemia</b>						
No	81/182	1		81/158	1	
Yes	271/615	0.91 (0.71–1.17)	0.454	275/522	0.92 (0.72–1.18)	0.499
<b>Hypercholesterolemia</b>						
No	90/216	1		27/58	1	
Yes	262/581	1.12 (0.88–1.42)	0.363	63/125	1.24 (0.79–1.95)	0.354
<b>Lipid-lowering medications</b>						
No	314/719	1		322/616	1	
Yes	38/78	1.38 (0.99–1.94)	0.059	34/64	1.26 (0.88–1.79)	0.208

(Continued to the next page)

Supplementary Table 1. Continued

Variable	CKD-EPI			MDRD		
	E/N	HR (95% CI)	P value	E/N	HR (95% CI)	P value
eGFR baseline tertiles <sup>a</sup>						
Top tertile	59/267	1		74/227	1	
Middle tertile	113/265	2.32 (1.69–3.18)	<0.001	127/227	2.05 (1.54–2.73)	<0.001
Low tertile	180/265	5.72 (4.25–7.69)	<0.001	155/226	3.49 (2.64–4.61)	<0.001
Positive history of CVD						
No	305/719	1		319/618	1	
Yes	47/78	2.54 (1.86–3.47)	<0.001	37/62	1.88 (1.33–2.64)	<0.001
Low physical activity						
No	97/237	1		98/206	1	
Yes	255/560	1.06 (0.84–1.34)	0.626	258/474	1.04 (0.82–1.31)	0.765
Educational level, yr						
>12	18/56	1		20/51	1	
6–12	93/283	0.98 (0.59–1.62)	0.937	110/225	1.10 (0.68–1.77)	0.705
<6	241/458	2.00 (1.24–3.23)	0.005	226/374	1.96 (1.24–3.10)	0.004
Smoking status						
Never	283/611	1		285/510	1	
Former	37/89	1.00 (0.71–1.40)	0.985	32/78	0.78 (0.54–1.12)	0.174
Current	32/97	0.71 (0.49–1.03)	0.067	39/92	0.78 (0.56–1.10)	0.153
Family history of CVD						
No	283/639	1		293/554	1	
Yes	69/158	0.98 (0.75–1.28)	0.889	63/126	0.92 (0.70–1.21)	0.537
Family history of DM						
No	174/398	1		182/346	1	
Yes	178/399	1.00 (0.81–1.23)	1.000	174/334	1.00 (0.82–1.24)	0.975

HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease; E/N, event/number; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; DM, diabetes mellitus.

<sup>a</sup>The range of e-GFR baseline tertiles: top tertile: eGFR >79.4 mL/min/1.73 m<sup>2</sup>; middle tertile: 70.0 ≤ eGFR ≤ 79.4 mL/min/1.73 m<sup>2</sup>; and bottom tertile: 60 ≤ eGFR <70.0 mL/min/1.73 m<sup>2</sup> for CKD-EPI analysis. Top tertile: eGFR >72.8 mL/min/1.73 m<sup>2</sup>; middle tertile: 66.2 ≤ eGFR ≤ 72.8 mL/min/1.73 m<sup>2</sup>; and bottom tertile: 60 ≤ eGFR <66.2 mL/min/1.73 m<sup>2</sup> for MDRD analysis.